Welcome to our dedicated page for Agenus news (Ticker: AGEN), a resource for investors and traders seeking the latest updates and insights on Agenus stock.
Agenus Inc. (NASDAQ: AGEN) is a pioneering clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. Agenus is steadfast in its mission to develop innovative immunological therapies aimed at leveraging the body's immune system to combat cancer and other diseases. The company’s diverse product pipeline includes immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc., and vaccine adjuvants through its subsidiary SaponiQx Inc. These products are bolstered by in-house capabilities such as current good manufacturing practice (cGMP) manufacturing and a clinical operations platform.
Agenus has developed several key product candidates, including botensilimab (AGEN1811), a next-generation Fc-engineered CTLA-4 antibody, and balstilimab, a PD-1 antibody. They are currently under investigation for their potential to treat various cancers, particularly difficult-to-treat solid tumors.
The company has achieved significant milestones, including the initiation of various clinical trials for botensilimab and balstilimab. Notably, in April 2024, Agenus announced a one-for-twenty reverse stock split of its issued and outstanding common stock to increase its stock price and meet Nasdaq Capital Market listing requirements. This move is part of a strategic plan to enhance future financing and qualify for inclusion in the Russell Indices.
In its ongoing pursuit of innovative cancer treatments, Agenus recently announced Phase 1 trial results demonstrating encouraging survival rates in patients with metastatic colorectal cancer. The Phase 2 data is expected to be submitted to a major medical conference in the latter half of 2024.
Agenus also engages in strategic partnerships to accelerate its development programs. For instance, a recent agreement with Ligand Pharmaceuticals secures a $100 million capital infusion, specifically aimed at supporting the clinical development and launch readiness of the BOT/BAL combination therapy.
The team at Agenus comprises scientists, researchers, biotechnologists, physicians, and business professionals united by the shared goal of achieving breakthroughs in cancer treatment. This collaborative spirit ensures that Agenus remains at the forefront of transformative cancer therapies, aiming to enhance patient outcomes and extend lives.
For more information, visit www.agenusbio.com or follow @agenus_bio on social media.
Agenus Inc. (NASDAQ: AGEN) announced a global exclusive license with Bristol Myers Squibb for its bispecific antibody program, AGEN1777, and received FDA clearance for an Investigational New Drug application. AGEN1777 targets inhibitory receptors on T and NK cells to enhance anti-tumor activity. The agreement includes a $200 million upfront payment and potential milestones totaling up to $1.36 billion. Phase 1 trials are set to begin in Q3 2021, focusing on safety and preliminary activity in patients with advanced solid tumors.
Agenus, a clinical-stage immuno-oncology company, will have its President and COO, Jennifer Buell, PhD, present at the Raymond James 2021 Human Health Innovation Conference on June 22, 2021, from 8:40 a.m. to 9:10 a.m. ET. The presentation will focus on the company's extensive pipeline, which includes checkpoint antibodies, cell therapies, and vaccines to activate immune responses against cancer and infections. The session will be available via a live webcast on their website.
Agenus Inc. (NASDAQ: AGEN) announced that the FDA accepted its Biologics License Application for balstilimab, an anti-PD-1 antibody aimed at treating recurrent or metastatic cervical cancer post-chemotherapy. The FDA granted Priority Review for this drug, indicating potential for significant treatment improvement. A target action date is set for December 16, 2021. Cervical cancer remains a major health issue, with an estimated 14,000 diagnoses and 4,000 deaths in the U.S. annually. The drug, currently in Phase 2 trials, could provide new options for patients facing limited treatment alternatives.
Agenus (NASDAQ: AGEN) announced its virtual Annual Shareholders Meeting to be held on June 15, 2021, at 5:00 p.m. ET. Registration will start at 4:45 p.m. ET, and shareholders can participate by visiting the provided link and entering their control number. Guests can listen in without a number. A live webcast will be available on the company's website. Agenus focuses on developing immuno-oncology therapies aimed at enhancing the immune response against cancer. For more information, stakeholders can visit the company's website.
Agenus (NASDAQ: AGEN) presented data at ASCO 2021, highlighting balstilimab's efficacy as an anti-PD-1 antibody and AGEN2373's favorable safety profile in a Phase 1 trial. Balstilimab demonstrated a 20% response rate in PD-L1 positive tumors and an overall 15% response rate in recurrent cervical cancer. AGEN2373 showed no liver toxicity in patients treated, reporting stable disease in 5 of 22 patients. The company submitted a Biologics License Application for balstilimab on April 19, 2021, aiming for broader therapeutic applications.
Agenus (NASDAQ: AGEN) will have its President and COO, Jennifer Buell, PhD, participating in a fireside chat at the Jefferies 2021 Virtual Healthcare Conference. This event is scheduled for June 4, 2021, from 10:30 a.m. to 10:55 a.m. ET. Interested attendees can register in advance for the webinar. A replay of the session will be made available on the Agenus Events & Presentations page following the call. Agenus is focused on immuno-oncology, developing therapies to enhance the immune response against cancer.
Agenus (NASDAQ: AGEN) announced promising data for its anti-PD-1 antibody, balstilimab, showcasing a 20% response rate in PD-L1 positive tumors and 15% overall response rate during a Phase 2 trial for recurrent/metastatic cervical cancer. The FDA accepted a Biologics License Application for balstilimab on April 19. Additionally, new Phase 1 data for AGEN2373, a CD137 agonist antibody, revealed no dose-limiting toxicities and stable disease in five patients out of 19 treated. Both findings will be presented at the ASCO Annual Meeting from June 4-8, 2021.
Agenus (NASDAQ: AGEN) announced a conference call on May 18, 2021, at 8:30 a.m. ET to discuss a global licensing agreement with Bristol Myers Squibb. This agreement marks a significant milestone for Agenus, which focuses on immuno-oncology, developing therapies to activate the immune response against cancer. Interested parties can join the call via dial-in numbers or through the live webcast accessible on the company's website. Agenus aims to enhance patient outcomes in cancer treatment through its diverse therapeutic pipeline.
Agenus has entered into a definitive licensing agreement with Bristol-Myers Squibb granting the latter a global exclusive license to AGEN1777, a bispecific antibody in late preclinical development targeting TIGIT and another undisclosed receptor. Agenus will receive a $200 million upfront payment and up to $1.36 billion in milestone payments, along with tiered royalties on sales. Bristol-Myers Squibb will lead the development and commercialization of AGEN1777, which aims to improve anti-tumor activity in non-small cell lung cancer and other high-priority tumors.
Bristol-Myers Squibb (BMY) has secured a global exclusive license for Agenus' bispecific antibody AGEN1777, targeting TIGIT. The deal entails a $200 million upfront payment and additional potential milestones totaling up to $1.36 billion, plus royalties on sales. AGEN1777, designed to enhance anti-tumor activities, is currently in late preclinical development, with an IND application expected in Q2 2021. Bristol-Myers Squibb aims to advance AGEN1777 for high-priority tumor indications like non-small cell lung cancer, highlighting its commitment to immuno-oncology.
FAQ
What is the current stock price of Agenus (AGEN)?
What is the market cap of Agenus (AGEN)?
What does Agenus Inc. specialize in?
Where is Agenus Inc. headquartered?
What are the key products of Agenus Inc.?
What recent strategic financial move did Agenus make?
What significant agreement did Agenus secure recently?
What are some recent clinical trial achievements of Agenus?
What is the focus of Agenus' product candidates?
Who are part of the Agenus team?
How does Agenus support its product development?
Where can investors find more information about Agenus?
